Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 16/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352009 | 0.95 | MPO (0.74) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL517983 | 0.89 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL29571866 | 0.89 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL3702252 | 0.86 | MPO (0.67) | MPOSLC6A4 | |
| SCHEMBL4463073 | 0.85 | MPO (0.68) | MPOSLC6A4HTR2ATRPM8 | |
| SCHEMBL5584045 | 0.84 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL7846163 | 0.84 | MPO (0.77) | MPOSLC6A4HTR2ATRPM8 | |
| SCHEMBL4637101 | 0.84 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL3705476 | 0.84 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL7819881 | 0.83 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027607-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-9598401-B2 | Substituted heteroaryl compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-21 | — | — | US | disclosed |
| EP-3027607-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-06-08 | — | — | EP | disclosed |
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-03-24 | — | — | US | disclosed |
| WO-2015169180-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015014256-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-02-05 | — | — | WO | disclosed |
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| EP-0998474-B1 | PIPERAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-02-07 | — | — | EP | disclosed |
| EP-0993458-B1 | 3-BENZYLPIPERIDINE | MERCK PATENT GMBH (DE) | 2003-04-09 | — | — | EP | disclosed |
| CN-1093127-C | Piperazine derivatives | MERCK PATENT GMBH (DE) | 2002-10-23 | — | — | CN | disclosed |
| US-6333339-B1 | CENTRAL SYSTEM DISORDERS, SCHIZOPHRENIA AND COGNITION ACTIVATORS | MERCK PATENT GELLSCHAFT MIT BESCHRANKTER (DE) | 2001-12-25 | — | — | US | disclosed |
| US-6251908-B1 | Piperazine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-06-26 | — | — | US | disclosed |
| CN-1264379-A | Piperazine derivatives | MERCK PATENT GMBH (DE) | 2000-08-23 | — | — | CN | disclosed |
| CN-1260791-A | 3-benzylpiperidine | MERCK PATENT GMBH (DE) | 2000-07-19 | — | — | CN | disclosed |
| EP-0998474-A1 | PIPERAZINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2000-05-10 | — | — | EP | disclosed |
| EP-0993458-A1 | 3-BENZYLPIPERIDINE | MERCK PATENT GmbH (DE) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999003855-A1 | PIPERAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998057953-A1 | 3-BENZYLPIPERIDINE | MERCK PATENT GMBH (DE) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HTR3B, HTR3A, HTR2C | MPO 3540/4885SLC6A4 19/4885HTR2A 5/4885 |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | MPO 4022/4885SLC6A4 33/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.